June 2024

NEWARK, Del. and NANJING, China, June 11, 2024 /PRNewswire/ — Biosion, a global, clinical-stage biotechnology company, today presented key results from the ADAMANT study, a phase 2 proof-of-concept trial in AD subjects treated with Bosakitug, a high potency anti-TSLP mAb, in a podium presentat

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: